Jazz Pharmaceuticals plc revealed on 3 February that it is paying a big premium to add the high-growth rare epilepsy drug Epidiolex (cannabidiol) to its commercial portfolio and additional cannabinoid therapeutics to its pipeline with the $7.2bn purchase of GW Pharmaceuticals plc. The cash and stock transaction values GW Pharma at $220 per American depository share (ADS), which is 50% more than the London-based firm’s 2 February closing ADS price of $146.25.
During an investor call, Jazz chairman and CEO Bruce Cozadd declined to disclose whether the purchase price for GW reflects...








